US Bancorp’s Unity Biotechnology UBX Stock Holding History

US Bancorp’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-200	Closed	-$326	–	4138
2023 Q1	$326	Hold	200	–	–	﹤0.01%	3996
2022 Q4	$548	Hold	200	–	–	﹤0.01%	3994
2022 Q3	$1K	Sell	200 -800	-80%	-$5.05K	﹤0.01%	4014
2022 Q2	$6K	Hold	1,000	–	–	﹤0.01%	3547
2022 Q1	$11K	Buy	+1,000	New	+$11.2K	﹤0.01%	3352
2018 Q4	–	Sell	-92	Closed	-$15K	–	3699
2018 Q3	$15K	Buy	+92	New	+$15.1K	﹤0.01%	3011

Other funds holding UBX

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

FFVM

Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

US Bancorp's UBX Position: Q2 2023 in Review

US Bancorp sold out of Unity Biotechnology (UBX) in Q2 2023, closing a stake of 200 shares — an estimated $326 sold.

US Bancorp first reported a position in UBX in Q3 2018 and held it in 6 quarters. The position peaked at $15K in Q3 2018. 40 funds tracked by Wall St. Rank hold UBX as of Q2 2023.

US Bancorp reported no remaining Unity Biotechnology position as of Q2 2023 after selling out during the quarter.
US Bancorp sold 200 Unity Biotechnology shares in Q2 2023, an estimated $326.
US Bancorp first reported a position in Unity Biotechnology in Q3 2018 and held it in 6 quarters.
US Bancorp's Unity Biotechnology position peaked at $15K in Q3 2018.
40 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2023.

Based on US Bancorp's 13F filing for Q2 2023, filed 10 Aug 2023.